ReviewVeterinary sciences2026
Research Progress of GP4 Protein of Porcine Reproductive and Respiratory Syndrome Virus.
Review in Veterinary sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Porcine reproductive and respiratory syndrome, a highly contagious disease, poses a severe threat to the global swine industry. Its causative agent, PRRSV, induces reproductive disorders (abortion, stillbirth) in pregnant sows and respiratory disease in piglets. The host immune system is disrupted by PRRSV, and no specific antiviral drugs are currently available. Thus, vaccination is regarded as the primary strategy for PRRS prevention and control. GP4, a key minor structural protein of PRRSV with an estimated molecular weight of 32 kDa, contains four conserved N-glycosylation sites at residues 37, 84, 120 and 130. Critical neutralizing epitopes are harbored in its extracellular domain (amino acids 40-79). PRRSV binding to the host CD163 receptor is mediated by GP4, which also regulates viral assembly and release, and induces protective immune responses. Hence, GP4 is identified as a central target for PRRS vaccine development. In this review, GP4's structural characteristics, genetic evolution and interaction mechanisms are summarized. Its roles in viral life cycle, virulence, immune evasion and potential applications are discussed, providing a theoretical reference for PRRSV control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.